Seeking Alpha

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM ...
Nasdaq

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to ...
Nasdaq

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

-- Approval based on data from PIONEER trial, in which AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo1 -- CAMBRIDGE, Mass., Dec.
ksn.com

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug ...
Healthline

What Is Systemic Chemotherapy?

Systemic chemotherapy is when chemotherapy drugs travel throughout your body. This type of chemotherapy can be given intravenously or orally. Chemotherapy, or “chemo,” is a type of cancer treatment ...
FOX31 Denver

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental ...